Skip to main content

Table 1 Clinicopathological characteristics of the whole cohort and four subgroups of patients with pT3/4N0M0 HCC *

From: Application of tumor-node-metastasis staging 2002 version in locally advanced hepatocellular carcinoma: is it predictive of surgical outcome?

Characteristics

Whole cohort (n = 298)

Major vascular invasion (n = 21)

Multiple tumors more than 5 cm (n = 108)

Invasion of adjacent organs (n = 32)

Perforation of visceral peritoneum (n = 57)

Gender, Male:Female

276:22

20:1

100:8

30:2

51:6

Age (years)

48.0 ± 10.7

48.4 ± 12.5

46.1 ± 10.6

49.0 ± 8.2

45.6 ± 10.1

HBsAg positive

257 (86.2%)

17(81.0%)

85(78.7%)

26(81.3%)

51(89.5%)

HCVAb positive

18 (6.0%)

1(4.8%)

3(2.8%)

2(6.3%)

3(5.3%)

ALB (g/L)

42.7 ± 5.4

40.0 ± 4.8

43.1 ± 5.1

39.7 ± 5.7

43.4 ± 5.2

TBIL (μmol/L)

17.0 ± 9.5

18.0 ± 10.9

16.4 ± 9.6

17.6 ± 10.1

16.6 ± 5.9

PT (s)

13.6 ± 1.8

13.9 ± 2.5

13.6 ± 1.9

14.2 ± 2.1

13.0 ± 1.9

ICGR15 (%)

11.1 ± 6.4

12.9 ± 6.8

10.0 ± 5.6

10.3 ± 4.3

8.2 ± 2.8

AFP (μg/L) median (range) †

488 (1-332318)

2839(76-46135)

487(1-332318)

151.5(2-32318)

817(2-266360)

Child-Pugh A

260 (87.6%)

19(90.5%)

97(89.8%)

27(84.4%)

48(84.2%)

MELD score median (range)

7 (6-14)

7(6-9)

7(6-14)

7(6-11)

7(6-10)

Cirrhosis

241 (80.9%)

17(80.9%)

89(82.4%)

26(81.3%)

45(78.9%)

Tumor size (cm)

9.7 ± 3.8

8.6 ± 2.70

9.1 ± 3.0

10.9 ± 3.5

8.8 ± 2.8

Tumor encapsulation

87 (29.2%)

5(23.8%)

36(33.3%)

8(25.0%)

14(24.6%)

Microvascular invasion‡

187 (62.8%)

21(100%)

51(47.2%)

20(62.5%)

32(56.1%)

Resection margin > 0 mm

110 (36.9%)

6(28.6%)

39(36.1%)

12(37.5%)

19(33.3%)

Major hepatic resection

217 (72.8%)

16(76.2%)

81(75%)

21(65.6%)

38(66.7%)

Blood loss, liters

0.8 ± 0.5

0.9 ± 0.4

0.8 ± 0.6

0.7 ± 0.4

0.8 ± 0.7

Blood transfusion

157 (52.7%)

14(66.7%)

57(53.3%)

22(68.7%)

36(63.2%)

Previous TACE

16 (5.4%)

1(3.1%)

5(4.6%)

2(6.3%)

2(3.5%)

Postoperative adjuvant TACE

76 (25.5%)

6(28.6%)

32(33.3%)

7(21.9%)

9(15.8%)

  1. Unless otherwise stated, continuous data are expressed as mean ± SD; other figures indicate number of patients.
  2. HBsAg, hepatitis B surface antigen; HCVAb, hepatitis C virus antibody; ALB, albumin; TBIL, total bilirubin; PT, prothrombin time; ICGR15, indocyanine green retention rate at 15 minutes; AFP, α-fetoprotein; MELD, model for end-stage liver disease; TACE, transarterial chemoembolization.
  3. * The four subgroups were selected patients in whom the four pathologic features present singularly.
  4. † Serum AFP levels of patients with major vascular invasion were significantly higher than those of the other three subgroups (P < 0.05).
  5. ‡ The proportion of patients with microvascular invasion was significantly higher in patients with major vascular invasion than in the other three subgroups (P < 0.05).
  6. There were no significant differences between any groups in any other parameters.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us